Medtronic (NYSE:MDT) CEO Geoffrey Martha Sells 50,000 Shares of Stock

Medtronic PLC (NYSE:MDT) CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medtronic Trading Down 0.7%

NYSE MDT traded down $0.66 during trading hours on Friday, hitting $94.79. 30,274,266 shares of the company’s stock were exchanged, compared to its average volume of 11,408,682. The stock has a 50-day simple moving average of $90.87 and a 200 day simple moving average of $84.95. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The firm has a market cap of $121.25 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 2.15 and a beta of 0.55. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the company posted $1.26 earnings per share. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Analyst Ratings Changes

A number of research analysts recently issued reports on MDT shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $92.00 target price on shares of Medtronic in a research report on Thursday, September 3rd. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Wednesday. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Finally, Mizuho set a $115.00 price objective on shares of Medtronic in a report on Wednesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $102.88.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Institutional Trading of Medtronic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hengehold Capital Management LLC increased its position in shares of Medtronic by 1.7% during the third quarter. Hengehold Capital Management LLC now owns 42,768 shares of the medical technology company’s stock worth $3,690,000 after acquiring an additional 733 shares in the last quarter. Cardinal Capital Management Inc. raised its holdings in shares of Medtronic by 3.4% in the 3rd quarter. Cardinal Capital Management Inc. now owns 340,500 shares of the medical technology company’s stock worth $29,382,000 after acquiring an additional 11,325 shares during the last quarter. Cyndeo Wealth Partners LLC lifted its position in Medtronic by 4.6% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 7,680 shares of the medical technology company’s stock valued at $663,000 after acquiring an additional 339 shares in the last quarter. Pension & Wealth Management Advisors Inc. lifted its position in Medtronic by 64.1% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 2,556 shares of the medical technology company’s stock valued at $221,000 after acquiring an additional 998 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. boosted its stake in Medtronic by 2.0% during the 3rd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 167,041 shares of the medical technology company’s stock valued at $14,414,000 after purchasing an additional 3,243 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.